Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)

NCT03160339 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT03160339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03160339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
Lead sponsor
Emergent BioSolutions
Phase
Phase 1
Overall status
Terminated
Start date
May 1, 2017
Completion date
November 27, 2017
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoviral infection